Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 for 12 Weeks in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Nemiralisib (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors GlaxoSmithKline; GSK
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 16 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 19 Oct 2018.